In this May 10, 2023 Agilent Technologies (A) post, I disclose the addition of this Diagnostic & Research company to the FFJ Portfolio to go along with my exposure to Danaher Corporation (DHR); DHR posts are accessible through the Archives section of this site. I like the long-term outlook of the Diagnostic and Research industry. [...]
In previous posts, I have explained my rationale for investing in BlackRock (BLK) and Blackstone (BX) for the long term. I, therefore, dispense with a review of these two companies and merely provide this brief post to disclose the following additional purchases on May 9: BLK - acquired 30 shares @ $635.349 bringing my total [...]
This JP Morgan (JPM) post is my 4th guest post about North American banks at Dividend Power. The following are links to the previous 3 posts. Scotiabank (BNS) Is A Terrible Long-Term Investment TD Bank Is A Top 10 North American Bank CIBC Is An Accident Waiting To Happen All investments require the assessment [...]
I regret not having requested approval from my employers' compliance teams to permit me to invest in many of the companies with which I had dealings over the years as many of these companies have gone on to generate extremely attractive total investment returns. Agilent Technologies (A) is one such company. I initially became aware [...]
In my November 25, 2022 West Pharmaceutical (WST) post, I disclosed a new position in WST with the purchase of 100 shares @ ~$225/share in one of the 'Core' accounts within the FFJ Portfolio. I would have acquired a larger number of shares, however, I stated: 'In recent posts, I mention the purchase of a [...]
While Canada has a relatively strong banking system, not all Canadian banks warrant consideration as a long-term investment. In January, I suggested investors pass on Scotiabank in my Scotiabank (BNS) Is A Terrible Long-Term Investment guest post published at Dividend Power. I subsequently wrote my TD Bank (TD) guest post at Dividend Power in which [...]
I last reviewed Intuitive Surgical (ISRG) in this October 19, 2022 post at which time I concluded that: A drawback with ISRG is that its valuation is rarely attractive. While its current valuation appears high, this is a high-growth company (~$2.2B of annual revenue in FY2012 versus ~$4.6B in the first 3 quarters of FY2022). [...]
Before initiating a position in Lockheed Martin (LMT), I had exposure to the aerospace and defence industry through share ownership in Raytheon Technologies (RTX) and Heico Corporation (HEI-a). However, I expected the number of global 'hot spots' to increase and wanted more exposure to this industry. Looking at The Council on Foreign Relations website's Global [...]
In times of uncertainty, it helps if we use common sense when it comes to investing. Before I delve into why Paychex (PAYX) should appeal to risk-averse investors, I provide goeasy Ltd. (GSY.to) as an example of a company that should alarm investors; I touched upon this company in my December 27, 2020 post. GSY [...]
I can't think of a more fitting image for this post than to show how Berkshire Hathaway (BRK) has performed relative to the S&P500 (with dividends included) in just under 60 years. For several years I have trusted BRK in times of uncertainty. Now that I am helping a couple of young investors with minimal [...]